CAD 0.03
(0.0%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | - CAD | 0.0% |
2022 | - CAD | 0.0% |
2021 | - CAD | 0.0% |
2020 | - CAD | -100.0% |
2019 | 39.19 Thousand CAD | -62.47% |
2018 | 104.44 Thousand CAD | 0.0% |
2017 | 104.44 Thousand CAD | 0.0% |
2016 | - CAD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q1 | - CAD | 0.0% |
2023 Q4 | - CAD | 0.0% |
2023 Q2 | - CAD | 0.0% |
2023 Q1 | - CAD | 0.0% |
2023 Q3 | - CAD | 0.0% |
2023 FY | - CAD | 0.0% |
2022 FY | - CAD | 0.0% |
2022 Q2 | - CAD | 0.0% |
2022 Q3 | - CAD | 0.0% |
2022 Q4 | - CAD | 0.0% |
2022 Q1 | - CAD | 0.0% |
2021 Q1 | - CAD | 0.0% |
2021 FY | - CAD | 0.0% |
2021 Q4 | - CAD | 0.0% |
2021 Q3 | - CAD | 0.0% |
2021 Q2 | - CAD | 0.0% |
2020 Q4 | - CAD | 100.0% |
2020 Q3 | -722.01 Thousand CAD | 0.0% |
2020 Q1 | 1.00 CAD | -100.0% |
2020 FY | - CAD | -100.0% |
2020 Q2 | - CAD | -100.0% |
2019 Q2 | 104.44 Thousand CAD | 0.0% |
2019 Q1 | 104.44 Thousand CAD | 0.0% |
2019 FY | 39.19 Thousand CAD | -62.47% |
2019 Q4 | 39.19 Thousand CAD | 0.0% |
2019 Q3 | 39.19 Thousand CAD | -62.47% |
2018 Q4 | 104.44 Thousand CAD | 0.0% |
2018 FY | 104.44 Thousand CAD | 0.0% |
2018 Q3 | 104.44 Thousand CAD | 0.0% |
2018 Q1 | - CAD | -100.0% |
2017 Q4 | 104.44 Thousand CAD | 0.0% |
2017 FY | 104.44 Thousand CAD | 0.0% |
2016 FY | - CAD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
Eupraxia Pharmaceuticals Inc. | 1.00 CAD | 100.0% |
Helix BioPharma Corp. | - CAD | NaN% |
Microbix Biosystems Inc. | 5.75 Million CAD | 100.0% |
Medicenna Therapeutics Corp. | - CAD | NaN% |
Satellos Bioscience Inc. | -583 Thousand CAD | 100.0% |
Oncolytics Biotech Inc. | - CAD | NaN% |
Sernova Corp. | - CAD | NaN% |